A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...
Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
Clinical Trials Arena on MSN6d
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drugCompared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...
Mural Oncology (NASDAQ:MURA – Get Free Report) had its target price lowered by equities researchers at HC Wainwright from $18 ...
A replay of the webcast Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for ...
The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback